Navigation Links
Jennerex Announces First Patient Treated in Phase 2 Clinical Trial of Intravenous Delivery JX-594 In Patients with Advanced Liver Cancer
Date:7/25/2012

potential to impact both metastatic and primary tumors. In our previously reported randomized Phase 2 dose-ranging study in HCC with intratumoral delivery, we showed a statistically significant benefit in overall survival in the high dose group, which we believe was due, in large part, to the systemic delivery of JX-594 at that dose level."

JX-594: A Multi-Mechanistic Approach To Targeting Cancer

JX-594 is a proprietary, engineered oncolytic immunotherapy designed to selectively target and destroy cancer cells through three diverse mechanisms of action: 1) the lysis of cancer cells through viral replication, 2) the shutdown of the blood supply to tumors through vascular targeting and destruction, and 3) the stimulation of the body's immune response against cancer cells, i.e., active immunotherapy. Phase 1 and Phase 2 clinical trials in multiple cancer types to date have shown that JX-594, delivered either directly into tumors or intravenously, induces tumor shrinkage and/or necrosis and is well-tolerated by patients (over 130 treated to date). Objective tumor responses have been demonstrated in a variety of cancers including liver, colon, kidney, lung cancer and melanoma. JX-594 has had a favorable safety profile to date with predictable and generally mild side effects that typically include flu-like symptoms that resolve in 24 to 48 hours.

JX-594 is the most advanced product candidate from Jennerex's proprietary SOLVE™ (Selective Oncolytic Vaccinia Engineering) platform.  SOLVE takes advantage of the natural attributes of poxviruses as well as their potential to be engineered to produce oncolytic immunotherapies that can target and destroy solid tumors both systemically and locally.  The vaccinia poxvirus strain backbone of JX-594 has been used safely in millions of people as part of a worldwide vaccination program. This strain naturally targets cancer cells due to common genetic abnormalities in cancer cells. JX-594 was engin
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Jennerex Appoints Dr. Laurent Fischer as President and Chief Executive Officer
2. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
3. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
4. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
5. Misonix Announces New Distribution Agreement For Panama
6. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
7. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
8. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
9. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
10. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
11. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Hearing health affects a man,s lifestyle, and if he wants ... engaged, he should address any hearing loss he may be ... Hearing Institute (BHI) is delivering to men around the ... which leads up to and includes Father,s Day. This year, ... 16. To help men address their hearing ...
(Date:5/23/2013)... , May 23, 2013  A recently published clinical ... Houston, Texas , demonstrates that 3D mammography ... cancer detection. The study, "Implementation of ... Study," was led by Stephen L. Rose ... of the American Journal of Roentgenology (AJR). ...
(Date:5/23/2013)... JERUSALEM , May 23, 2013  Hadasit Bio-Holdings ... portfolio of biotech companies, based on intellectual property ... Israel ,s foremost medical research center, ... Neurosciences Ltd., received significant funding from the Israeli ... Chief Scientist (OCS) to support product development and ...
Breaking Medicine Technology:Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 2Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 3Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 4First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 2First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 3Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
... YONKERS, N.Y.--(BUSINESS WIRE)--Jun 18, 2007 - Advanced ... biopharmaceutical,company, announced today that preliminary findings from ... treatment with AVR118,appears to have clinical activity ... incisions or dermatologic,dermabrasion., The Phase II open ...
... -- More than 70 abstracts highlight VELCADE efficacy ... care --, CAMBRIDGE, Mass., June 19, 2007 /PRNewswire-FirstCall/ ... the market leading therapy with unsurpassed single-agent,efficacy for ... featured at the upcoming International Myeloma,Workshop (IMW) in ...
Cached Medicine Technology:Advanced Viral Research Corp. Announces Positive Preliminary,Findings from Ongoing Phase II Dermatological Study 2Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 2Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 3Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 4Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 5Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 6Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 7Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 8
(Date:5/23/2013)... 2013 Over the past decade, the ... which has affected the Medical Group Practice Management ... regular hours, more young physicians are opting out of ... groups,” says IBISWorld industry analyst Anna Son. In addition, ... number of older physicians are selling their practices and ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Whether working ... Operations Forces and law enforcement need an added layer ... Security Enhancer, Night VISER , is an effective ... motion sensing system to increase border and perimeter security. ... VISER have more than tripled over the past three ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Vegas ... is pleased to announce all new vacation packages ... in coming to Las Vegas for this patriotic ... it is thanks to VegasHotelEscapes.com's new special pricing ... to state that it guarantees the lowest prices ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Funeral Financials ... Memorial Day to the EOD Memorial Foundation ... be the greatest victims from the war. , ... originated in 1941 before the U.S. was even at ... Forces are identified with the Explosive Ordnance Disposal Badge. ...
(Date:5/23/2013)... -- A modified version of the polio virus ... research suggests. Scientists at Duke Cancer Institute ... uses an engineered form of the virus that ... cells. The therapy shows promise in the treatment ... tumor, they said. "These early results are ...
Breaking Medicine News(10 mins):Health News:Medical Group Practice Management in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Medical Group Practice Management in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Lighting Up the Night: ARA Announces Record Sales of Its Night VISER System 2Health News:Lighting Up the Night: ARA Announces Record Sales of Its Night VISER System 3Health News:Funeral Financials Asks Americans to Donate their Memorial Day Beer Money to Help EOD Scholarship 2Health News:Funeral Financials Asks Americans to Donate their Memorial Day Beer Money to Help EOD Scholarship 3Health News:Modified Polio Virus May Help Fight Brain Tumors, Study Suggests 2
... Nov. 1 It is estimated more than two ... States, with about,one-in-six expected to get the disease at ... Society. Thankfully, new treatment,technologies are making surviving the disease ... and more Americans are too large to be treated,using ...
... Nov. 1 The Michael J. Fox,Foundation (MJFF) ... 2008 Target Validation effort. Under this annual program ... 2008 for projects designed to validate the,therapeutic potential ... possible pharmaceutical industry investment and clinical trials., ...
... discovered a novel mechanism to predict survival in older ... have significant implications for new treatment approaches. , For ... aromatase, an enzyme that naturally makes estrogen from another ... survival rates in women over 65 with Stage 1 ...
... do not necessarily have worse outcomes after liver transplantation. ... they fare just as well. These are the results ... Hepatology, a journal published by John Wiley & Sons ... of Liver Diseases (AASLD). The article is also available ...
... carbon nanotubes can be destroyed by non-invasive radio waves ... a research team led by scientists at The University ... University has shown in preclinical experiments. , In a ... journal Cancer, researchers show that the technique completely destroyed ...
... keeping good track of daily blood sugar levels, while ... -- Fewer American adults with diabetes are developing cardiovascular ... blood sugar levels, according to new U.S. government research ... and Prevention studies, published in the CDC,s weekly journal ...
Cached Medicine News:Health News:Michael J. Fox Foundation Commits Up to $2 Million for PD Drug Development Under Target Validation 2008 2Health News:Researchers discover new way to predict survival in older women with lung cancer 2Health News:Researchers discover new way to predict survival in older women with lung cancer 3Health News:No racial differences seen in outcomes after liver transplantation 2Health News:Radio waves fire up nanotubes embedded in tumors, destroying liver cancer 2Health News:Radio waves fire up nanotubes embedded in tumors, destroying liver cancer 3Health News:Adults With Diabetes Doing Better Prevention Job 2
The new Vascular ClearWay Irrigating PTFE Balloon Catheter is a revolutionary micro-porous PTFE balloon catheter designed for the removal of fresh, soft emboli and thrombi, and for intraluminal irrig...
... for every general surgery need. No matter ... the GO450/GO400 Omni-Flex™ General Retractor Systems give ... the best possible exposure in the simplest ... and the hinged extension arm, the GO450 ...
... gelatinase-associated lipocalin, lipocalin-2) is a new early ... renal failure with a >90% positive predictive ... urine, as early as 2 hours after ... diagnostic marker for acute renal failure. ,Quantitative ...
... Don't miss the sounds you ... lung, and other body sounds ... with the Littmann Model 3000., ... technology, up to 18 times ...
Medicine Products: